

# ESMO in Focus Lung Cancer Conference

## May 8 -9, 2026

### Friday, May 8, 2026

Time	Session/Title	Speaker
09:00 – 09:10	Opening	Mircea Dediu, Laura Mazilu
	Chairs: Mircea Dediu, Laura Mazilu	
09:10 – 09:30	Should we still consider classical surgery first followed by adjuvant treatment in early stage NSCLC?	Tudor Ciuleanu
09:30 - 09:50	Stage III NSCLC – Navigating the borderline between Neoadjuvant Strategy and Definitive Chemoradiotherapy	Dana Clement
09:50 – 10:10	How to integrate ctDNA assessment in the management of NSCLC	Șerban Negru
10:10 – 10:30	Re-treatment with immunotherapy: any available evidences?	Laura Mazilu
10:30 – 10:50	Managing Immune-Related Adverse Events: A Practical Approach	Amedeia Niță
10:50 – 11:10	Addressing the KRAS mutation targeted treatment in NSCLC	Răzvan Ovidiu Curcă
11:10 - 11:30	<b>Coffee Break</b>	
11:30 - 12:00	MSD Symposium KEYTRUDA, the key to more possibilities for patients with NSCLC in early-stage disease	Dana Clement Mircea Dediu
12:00 – 12:15	Pfizer Symposium Start strong in the first line for ALK+ NSCLC: the role and importance of Lorlatinib	Tudor Ciuleanu
12:15 – 12:35	Johnson & Johnson Symposium Rybrevant® redefines the management of patients with EGFR+ NSCLC with exon insertion	Tudor Ciuleanu
12:35 – 12:55	Merck Symposium Tepotinib, a step forward in managing NSCLC -	Mircea Dediu
12:55 – 13:10	Accord Symposium Bone Metastases in Lung Cancer: Clinical Challenges and Emerging Therapeutic Opportunities in the Era of Immunotherapy and Modern Multimodal Approaches	Mircea Dediu
13:10 -13:40	Roche Symposium Tecentriq® - Redefining the standard of care for treatment of ES-SCLC	Paul Kubelac
13:40 – 13:45	Break	
13:45- 14:15	Working Lunch – Medison Symposium From detection to clinical decision: the critical role of MDT collaboration in lung cancer	Moderat: Laura Mazilu Șerban Negru Cristian Oancea Ovidiu Pop
14:15 – 14:25	Break	

	<b>Chair: Dana Clement, Mircea Dediu</b>	
14:25 – 14:45	The Role of Psychological Support in Lung Cancer	Ramona Schenker
14:45 – 15:05	Genomic Signature of Lung Cancer – Liquid Biopsy and Precision Medicine	Viorica Radoi
15:05 – 15:25	Overcoming acquired resistance to osimertinib based therapy in EGFR mutant NSCLC	Dana Clement
15:25 – 15:45	<b>Coffee Break</b>	
15.45- 16:15	Medison Symposium Unlock new Horizons with Libtayo <ul style="list-style-type: none"> <li>From guideline to clinical practice - Defining the first move with Libtayo</li> <li>Unlocking Insights: Clinical case experience with Libtayo</li> </ul>	Moderat: Michael Schenker  Răzvan Ovidiu & Mircea Dediu  Amedeia Niță
	<b>Chair : Mircea Dediu, Șerban Negru</b>	
16:15-16:35	Oportunitati de tratament medicamentos ale cancerului pulmonar in Republica Moldova	Angela Munteanu (MD)
16:35 – 17:05	Lung Cancer Screening Program: Pros and Cons	Diana Ionescu
17:05 – 18:05	Tumour Board Critical Interval between neoadjuvant IO+CT and surgery (M1 BRA ) Metastatic NSCLC with PD-L1 ≥50% – Choosing Between Immunotherapy Alone and Chemo-Immunotherapy in Clinical Practice Clinical Case presentation	Vladimir Preoteasa  Dana Clement  Vlad Vornicu
18:05 – 18:10	Closing	Mircea Mediu

## Saturday, May 9, 2026

Time	Session/Title	Speaker
	Astra Zeneca Satelite Symposium	
09:00 – 09:15	Introduction	Șerban Negru
09:15 - 09:35	Optimising care across the resectable → borderline resectable NSCLC continuum	Giuseppe Banna
09:35 – 09:55	Overcoming resistance in mNSCLC: Treating Immune-Cold Mutations	Laura Mazilu
09:55 – 10:15	Reducing Recurrence rates in EGFR-Mutated Early-Stage NSCLC	Mircea Dediu
10:15- 10:40	Optimizing first-line treatment for EGFR-mutated mNSCLC: balancing efficacy, toxicity, and survival endpoints	Alfredo Addeo
10:40 – 11:00	Integrating immunotherapy in SCLC: addressing unmet needs and future combinations	Răzvan Ovidiu Curcă
11:00 – 11:20	<b>Coffee Break</b>	
SCLC Session	<b>Chair : Mircea Dediu, Laura Mazilu</b>	

11:20 – 11:40	SCLC genomically homogenous but transcriptionally different: any clinical implications?	Michael Schenker
11:40 – 12:00	PCI for SCLC in the immune therapy era: anything new?	Giuseppe Banna
	<b>Chair : Laura Mazilu, Mircea Dediu</b>	
12:00 – 12:20	Emerging role of BiTE in ED-SCLC	Laura Mazilu
12:20 – 12:40	The Emerging Role and Clinical Trial Updates of ADCs in Lung Cancer Treatment	Alfredo Addeo
12:40 – 13:40	BMS Symposium CheckMate 77T - The Journey Goes Further: Bridging Neoadjuvant Treatment Response to Perioperative Approach	Tudor Ciuleanu Mircea Dediu Mariano Provencio
13:40– 14:30	<b>Lunch</b>	
	<b>Chairs: Răzvan Ovidiu Curcă</b>	
14:30 – 14:40	Oncoresearch Platform – SNOMR connects Romanian oncology to European progress	Răzvan Ovidiu Curcă
14.40-15:20	RW data collection updates: retrospective initiatives and prospective initiatives in Romania	Răzvan Ovidiu Curcă
Debate Session	Mircea Dediu, Mariano Provencio	
15.20-16.00	Neoadj vs perioperative strategy	Mircea Dediu Mariano Provencio
16:00 – 16:20	<b>Coffee Break</b>	
16:20 – 17:40	Astra Zeneca Symposium Moderator: Laura Mazilu IMFINZI: One IO regardless of resectability in non-mNSCLC  IMFINZI: One IO across the Entire SCLC Spectrum  Redefining Survival in FLAURA2: TAGRISSO is the First and Only TKI with the Highest Demonstrated OS in EGFRm NSCLC	Giuseppe Banna  Amedeia Niță  Dana Clement
17:40 – 18:00	Updates in the mesothelioma managemnt	Lucian Miron
18:00 – 18:10	Closing	Mircea Dediu